Graft-versus-host disease (GvHD) remains the mainly cause of late non-relapse mortality following allogeneic hematopoietic cell transplantation. Advancements in novel immunosuppressive therapies and prophylactic regimens necessitate an update to current clinical guidance. This consensus provides updated evidence-based recommendations for GVHD prophylaxis, alongside the treatment of acute and chronic disease.
No takes yet. Share an insight, caveat, or question.
Funke et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: